. Author manuscript; available in PMC: 2022 Aug 1.

Published in final edited form as: Mol Cancer Ther. 2021 Dec 14;21(2):336–346. doi: 10.1158/1535-7163.MCT-21-0395

Table 1.

Entrectinib sensitivity in re-engineered Ba/F3 cell lines

Fusion	Mutation	ROS1 Domain	Entrectinib IC₅₀ (nmol/L)
CD74-ROS1	-		19.4 ± 2.3
CD74-ROS1	V1979A	Kinase	7.3 ± 1.1
CD74-ROS1	L1982F	Kinase	5.2 ± 0.3
CD74-ROS1	S1986T	Kinase	5.3 ± 0.9
CD74-ROS1	F2004C	Kinase	177 ± 9.8
CD74-ROS1	Q2012K	Kinase	19.7 ± 3.8
CD74-ROS1	G2032R	Kinase	> 2000
CD74-ROS1	D2033N	Kinase	21.4 ± 4.2
CD74-ROS1	M2073T	Kinase	11.4 ± 1.0
CD74-ROS1	D2113G	Kinase	21.4 ± 2.9
CD74-ROS1	I2239*	C-term truncation	10.6 ± 0.6
EZR-ROS1	-		5.2 ± 0.9
EZR-ROS1	A1924_I1934del	Juxtamembrane	3.4 ± 0.2
EZR-ROS1	F2004C	Kinase	79.2 ± 7.9
EZR-ROS1	G2032R	Kinase	767.0 ± 26.3
EZR-ROS1	D2113N	Kinase	15.9 ± 2.1